DK173560B1 - Rekombinant pseudomonas exotoxin omfattende ADP ribosylerende aktivitet og som mangler hele eller en del af domæne II fra d - Google Patents
Rekombinant pseudomonas exotoxin omfattende ADP ribosylerende aktivitet og som mangler hele eller en del af domæne II fra d Download PDFInfo
- Publication number
- DK173560B1 DK173560B1 DK199901377A DKPA199901377A DK173560B1 DK 173560 B1 DK173560 B1 DK 173560B1 DK 199901377 A DK199901377 A DK 199901377A DK PA199901377 A DKPA199901377 A DK PA199901377A DK 173560 B1 DK173560 B1 DK 173560B1
- Authority
- DK
- Denmark
- Prior art keywords
- exotoxin
- pseudomonas exotoxin
- modified
- plasmid
- toxin
- Prior art date
Links
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 title claims abstract description 31
- 230000000694 effects Effects 0.000 title claims abstract description 31
- 239000003053 toxin Substances 0.000 claims abstract description 30
- 231100000765 toxin Toxicity 0.000 claims abstract description 30
- 239000002596 immunotoxin Substances 0.000 claims abstract description 27
- 231100000608 immunotoxin Toxicity 0.000 claims abstract description 23
- 230000002637 immunotoxin Effects 0.000 claims abstract description 23
- 229940051026 immunotoxin Drugs 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 13
- 108020003175 receptors Proteins 0.000 claims abstract description 8
- 102000005962 receptors Human genes 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 239000003102 growth factor Substances 0.000 claims abstract description 5
- 210000005260 human cell Anatomy 0.000 claims abstract description 3
- 230000004048 modification Effects 0.000 claims abstract description 3
- 238000012986 modification Methods 0.000 claims abstract description 3
- 241000124008 Mammalia Species 0.000 claims abstract 4
- 210000004102 animal cell Anatomy 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 44
- 239000013612 plasmid Substances 0.000 claims description 40
- 108700012359 toxins Proteins 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 108020004414 DNA Proteins 0.000 claims description 23
- 239000012634 fragment Substances 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 231100000776 exotoxin Toxicity 0.000 claims description 13
- 239000002095 exotoxin Substances 0.000 claims description 13
- 231100001231 less toxic Toxicity 0.000 claims description 6
- 102000000588 Interleukin-2 Human genes 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 241000589516 Pseudomonas Species 0.000 claims description 3
- 230000005859 cell recognition Effects 0.000 claims description 3
- 239000013613 expression plasmid Substances 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 102000013585 Bombesin Human genes 0.000 claims description 2
- 108010051479 Bombesin Proteins 0.000 claims description 2
- 102000009025 Endorphins Human genes 0.000 claims description 2
- 108010049140 Endorphins Proteins 0.000 claims description 2
- 102400000321 Glucagon Human genes 0.000 claims description 2
- 108060003199 Glucagon Proteins 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 claims description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 2
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 2
- 229960004666 glucagon Drugs 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 229940040129 luteinizing hormone Drugs 0.000 claims description 2
- 239000000813 peptide hormone Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 3
- 102000004506 Blood Proteins Human genes 0.000 claims 2
- 108010017384 Blood Proteins Proteins 0.000 claims 2
- 102000004856 Lectins Human genes 0.000 claims 1
- 108090001090 Lectins Proteins 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000002523 lectin Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940053128 nerve growth factor Drugs 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 238000010188 recombinant method Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 abstract description 5
- 231100000053 low toxicity Toxicity 0.000 abstract description 3
- 210000000170 cell membrane Anatomy 0.000 abstract description 2
- 230000005945 translocation Effects 0.000 abstract description 2
- 230000007890 cytotoxin activity Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 89
- 235000018102 proteins Nutrition 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 12
- 230000005730 ADP ribosylation Effects 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 230000022534 cell killing Effects 0.000 description 11
- 238000001243 protein synthesis Methods 0.000 description 10
- 230000014616 translation Effects 0.000 description 10
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 9
- 239000000284 extract Substances 0.000 description 8
- 239000008188 pellet Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 101100321445 Arabidopsis thaliana ZHD3 gene Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102100031334 Elongation factor 2 Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010077519 Peptide Elongation Factor 2 Proteins 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 101150072531 10 gene Proteins 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 101000606416 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Acyltransferase PE Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
DK 173560 B1
Rekombinant pseudomonas exotoxin omfattende ADP ribosylerende aktivitet og som mangler hele eller en del af domæne II fra det native toxin, target bærer-toxin konjugat omfattende pseudomonas exotoxin, 5 ekspressionsplasmid omfattende ONA, sammensætning omfattende konjugat, anvendelsen af exotoxin og konjugat
Opfindelsen angår et modificeret pseudomonas exotoxin omfattende ADP ribosylerende aktivitet og som mangler 10 hele eller en del af domæne II fra det native toxin.
Opfindelsen angår endvidere et target bærer-toxin konjugat omfattende et pseudomonas exotoxin koblet til en target bærer, et ekspressionsplasmid omfattende DNA, en 15 sammensætning omfattende et konjugat samt anvendelsen af et exotoxin og et konjugat.
Toxiner er umådeligt kraftigt virkende celledræbende midler, der er ansvarlige for en hel række humane sygdomme.
20 På grund af deres høje aktivitet er disse stoffer blevet knyttet til monoklonale antistoffer for at danne cytotoxiske midler (immunotoxiner), der specifikt binder til target-celler. Disse immunotoxiner er derfor særdeles anvendelige ved cancerterapi.
25
Pseudomonas exotoxin A (PE) er et ekstremt aktivt monomert protein (molekylvægt 66 kd), der udskilles af pseudomonas aeruginosa, som hæmmer proteinsyntese i eukaryo-tiske celler ved inaktiveringen af forlængelsesfaktor 2 30 (EF-2) ved at katalysere dens ADP-ribosylering (katalyse re overførsel af ADP ribosylgruppen af oxideret NAD til EF-2).
2 DK 173560 B1
Intoxicationsprocessen antages at skride frem via følgende trin: først binder PE til celler gennem en særlig receptor på celleoverfladen. Herefter indternaliseres PE-receptorkomplekset ind i cellen. Til slut overføres PE 5 til cytosolen, hvor det enzymatisk hæmmer proteinsyntesen. Overførselsprocessen antages at ske fra en sur del, da cellulær intoxication forhindres af svage baser som f.eks. NH4+, der hæver pH i sure vesicler. Ved udsættelse for sure tilstande går det hydrophobe område af 10 PE ind i membranen, hvilket bevirker dannelse af en kanal gennem hvilke det enzymatiske område i forlænget form går ind i cytosolen.
US patentskrift nr. 4 545 985 omhandler at pseudomonas-15 toxin kemisk kan kobles til et antistof eller vækstfaktor. Imidlertid har disse kemisk forbundne toxiner vist sig at udvise uønskede toxicitetsniveuaer. Det vil derfor være en fordel at have toxiner der var højt målrettet mod specifikke celletyper uden det generelle celledrab, 20 der normal står i forbindelse med disse toxiner.
PE-holdige immunotoxiner opbygges ved først at omsætte nativt PE med iminothiolan. Denne omsætning tjener både til at indføre to nye sulfhydrylgrupper, der anvendes ved 25 kobling af et antistof til toxinet, og til at inaktivere bindingen af PE til dens egen receptor. Denne metodik hviler på den kemisk inaktivering af PE-bindingspladser for at formindske uønskede bivirkninger, der skyldes bindingen af PE til celler med PE receptorer. Medens 30 denne metode har været forholdsvis succesfuld med hensyn til at frembringe et specifikt celledræbende middel i vævskulturer og i tumorbærerne mus, har det ikke været muligt at administrere mere end 2 ug PE immunotoxin til en mus på 20 g eller 1 mg til en abe på 3 kg eller 4 mg DK 173560 B1 3 til et voksent menneske hvilket skyldes de toxiske bivirkninger ved immunotoxinet. Det er derfor ønskeligt at være i stand til at administrere større mængder immunotoxiner for at opnå større drab af tumorceller.
5
Den foreliggende opfindelse er i stand til at opfylde dette ønske ved at tilvejebringe et immunotoxin med kraftig aktivitet og lav toxicitet. Yderligere omfatter den foreliggende opfindelse for at løse ovennævnte 10 afhængighed af kemisk inaktivering af PE bindingspladser rekombinant DNA metoder for at klone det komplette toxingen {eller del heraf) for at udtrykke et højt niveau af det fuldlængdede toxinmolekyle (eller del heraf) indeholdende forskellige funktionelle områder, herunder 15 et, der mangler cellebindingsområdet. Se eksempel 1 der angiver en sammenlignende undersøgelse af disse kloner.
Den tredimensionale opbygning af PE er blevet bestemt ved røntgenkrystallografi. Som angivet i fig. 2 indeholder PE molekylet tre distinkte områder: området I indeholder 20 aminosyrerester 1-252 (område la) og 365-404 (område Ib); område II indeholder aminosyreresterne 253-364; og område III indeholder aminosyreresterne 405-613.
Man har opbygget plasmider, der udtrykker forskellige de-25 le af PE molekylet, hvilket giver muligheden for at correlere forskellige strukturelle områder med forskellige funktionelle aktiviteter og bestemme (1) hvilken de af molekylet, der er ansvarlig for cellegenkendelse (binding) , (det strukturelle område I, aminosyre 1-252); (2) 30 hvilken del, der kræves for enzymatisk aktivitet (ADP ribosylerende aktivitet, område III + en del af området Ib) (aminosyre 385-613); (3) hvilken del, der er ansvarlig for translokation tværs over cellemembranen (område II) . PE fra plasmider med en deletion af den 4 DK 173560 B1 første halvdel af det strukturelle område II udviser både PE blokerende virkning og ADP ribosylerende virkning, men disse molekyler har tabt al celledræbende aktivitet. Plasmider, der kun koder det strukturelle område III, 5 frembringer store mængder af proteinet, men mangler målelig enzymatisk aktivitet (ADP-ribosylering). Imidlertid udtrykker plasmider, der koder hele det strukturelle område III plus nabostillede aminosyrer fra det strukturelle område Ib store mængder protein, og deres ADP-ri 10 bosylerende aktivitet er høj.
Baseret på den tredimensionelle opbygning af PE er plasmider blevet opbygget, der udtrykker forskellige dele af PE. Proteinmønsteret af cellerne, der udtrykker forskel-15 lige opbygninger, analyseredes ved SDS gelelektrophorese, og den ADP ribosylerende aktivitet af de rekombinante toxiner blev målt. Blandt disse plasmider (beskrevet i eksempel 1) er plasmid pJH17, indeholdende aminosyrer fra område Ib), i stand til at kode for store mængder 20 modificeret PE, der udviser lav toxicitet over for humane celler, men som forbliver enzymatisk særdeles aktive.
Alt i alt kan det siges, at plasmidmønstrene indicerer, at det strukturelle område la er et receptorbindingsom-25 råde, at den første halvdel af det strukturelle område II er nødvendig for flytning af toxinet fra en værtscelles endocytiske vesicler til cytosolen, og at det strukturelle område III alene ikke er tilstrækkeligt til at udtrykke fuld ADP-ribosyleringsaktivitet.
30 Når PE administreres til dyr, dør disse på grund af leversvigt. Immunotoxiner fremstillet med PE angriber også leveren og dræber, når de indgives i store mængder, ogsåpå grund af levertoxicitet. Forsøgene angivet i tabel DK 173560 B1 5 III viser, at område la er ansvalig for cellebinding og viser, at et PE molekyle, hvori område la er deleteret, er mindre toxisk for mus end nativt PE. Resultaterne angivet i eksempel 4 understøtter denne konklusion, hvilket 5 indicerer, at modificeret PE er mindst 200 gange mindre toxisk over for mus end det native PE. Eksempel 5 viser, at dersom protein fremstilledes med pHJ8 renses og koblet til et antistof til den humane transferrinre-ceptor, frembringes et immunotoxin, der er omtrent så ak-10 tivt som et immunotoxin indeholdende nativt PE, men som er 100 gange mindre toxisk på ikke-target celler (museceller) .
15 Under henvisning til tegningen viser fig. 1 opbygningen af de omhandlede plasmider, der anvendes til udtrykkelse af forskellige områder af PE; 20 fig. 2 er et simplificeret kort over de forskellige størrelses PE molekyler frembragt som en del af opfindelsen; fig. 3 viser effekten af PE45-HB21 og PE-HB;i på proteinsyntesen i humane KB-celler. PE45 er toxinproteinet, der 25 mangler område I kodet af plasmid pJH8. Celler inkuberet 24 timer med det passende immunotoxin og inkuberedes dernæst med 3H-leucin i 1 time. Indarbejdning af (3H)-leucin ind i protein måltes. I fig. 3B inkuberedes schweisiske 3T3 celler i 24 timer enten med nativt pseu-30 domonastoxin (PE), nativt pseudomonastoxin koblet til HB21, PE45 alene eller PE45 koblet til HB21. Cellerne eksponeredes fra disse midler i 24 timer og herefter måltes proteinsyntese i 1 time som beskrevet ovenfor.
DK 173560 B1 6 I den foretrukne udførelsesform er den omhandlede fremstilling af den modificerede form af pseudomonas exoto xin (PE), hvor modifikationen bevirker i fremstillingen af et aktivt immunotoxin. Det modificerede toxin og immu-5 notoxinet fremstillet her ud fra har bemærkelsesværdig formindsket ikke specifik toxicitet over for humane og museceller i vævskultur og med betydelig nedsat toxicitet over mus in vivo.
10 Genom DNA fås ved fuldstændig nedbrydning af en stamme af pseudomonas aeruginosa med EcoRI og Pstl. Skønt en hvilken som helst stamme af P. aeruginosa er velegnet til anvendelse ved den foreliggende opfindelse, er den foretrukne PA103, en stamme, der frembringer en stor 15 mængde aktivt toxin. DNA fragmenterne, der ligger i størrelse fra 2,6 til 2,9 kb, isoleres fra det genome DNA bibliotek og ligeres med et 2,7 kb DNA fragment fra plasmid pUC13 afskåret med EcoRI og Pstl. Plasmid pUC13 er kommercielt tilgængeligt fra Boehringer Mannheim. En 20 passende vært, fortrinsvis en E. coli stamme, transformeres derefter med de ligerede produkter (den foretrukne stamme er E. coli HB101, der kommercielt kan fås fra Be-thesda Research Laboratories). 2,7 kb DNA fragmentet stammende fra ptoxETA, et plasmid, der indeholder det PE 25 strukturelle gen, anvendes som en probe, og plasmid DNA fra adskillige positive kolonier fremstilledes og karakteriseredes ved Southern blotting. De forskellige størrelser af rekombinant PE udtrykkes herefter i en passende vært. En vært, der bærer det bakteriofage T7 RNA poly-30 merasegen i lysogen og inducerbar form [BL21(DE3)1 foretrækkes, og kan fås fra Dr. F.W. Studier ved Brookhaven National Laboratories. Foretrukne er også plasmider, der bærer den bacteriofag sene T7 promotor og AMPr og Shine-Dalgarno box - pAR2156, der også kan fås fra Dr. Studier.
DK 173560 B1 7
Som angivet i eksempler er det foretrukne plasmid pJH17.
Plasmid pJH17 indeholder et DNA fragment på 4,8 kb og er 5 i stand til at udtrykke område III med de naboliggende 20 aminosyrer af PE. Dette plasmid frembringes ved fuldstændig afskæring af plasmid pJH4 med Hindlll og Apal.
4,8 kb DNA fragmentet isoleres derefter og inkuberes med klenow DNA polymerase I og dNTP for at udfylde de cohæsi-10 ve ender, hvorefter der ligeres med T4 ligase.
Udtrykkelse af rekorobinante toxiner i BL21(DE3) BL21(DE2) indeholdende plasmider til udtrykkelse af for-15 skellig størrelse PE dyrkes i LB bouillon med 50 ug ampi-cillin/ml ved 37 0C. Når absorbansen ved 650 nm når 0,3 sættes IPTG (isopropyl-_-D-thio-galatopyranosid) til kulturen til en slutkoncentration på 1 mM. Cellerne indhøstes 90 minutter senere og analyseres for mængden af 20 rekombinante toxiner ved hjælp af SDS-page immunoblot- ting, ADP-ribosylering og celledrabsforsøg.
SDS-PAGE og immunoblotting 25 Cellepellet opløses i Laemmli puffer. Prøverne kogtes i 5 minutter inden anbringelse på en 0,1% SDS, 10% acryl-amidskivegel. Til immunoblotting overførtes prøver efter elektrophorese til et nitrocellulosepapir efterfulgt af omsætning med antistof over for PE, herefter et andet an-30 tistof (gede anti-kanin) og farvning. Antistoffet over for PE fås ved hyperimmunisering af kaniner med glutaral-dehyd (0,2%) omsat PE (250 ug PE pr. injektion). En IgG fraktion fremstilledes til immunoblotting.
DK 173560 B1 8
Undersøgelse af ADP-ribosyleringsaktivitet
Kendte metoder anvendes til undersøgelse for ADP-ribosyleringsaktivitet. Kort fortalt anvendes kanin reticulo-5 cytpræparater eller hvedekimsekstrakter beriget med forlængelsesfaktor 2 (EF-2) som kilde for EF-2. Prøver (500 μΐ totalrumfang) indeholdende ca. 10 pmol EF-2, 37 pmol 14C-NAD (0,06 pCi) , 0,25-1,25 μg pE og puffer (40 mM DTT, 1 mM EDTA og 50 mM Tris, pH 8,1). Aktivitet måles som 10 pmol NAD overført til EF-2 iløbet af 30 minutter. En standardkurve med kendte koncentrationer af PE optegnes og anvendes til bestemmelse af aktiviteten af PE i ekstrakter fra E. coli. Efter inkubation i 30 minutter ved 37 0C sættes 0,5 ml 12% TCA til hver forsøgsblanding.
15 Herefter anbringes forsøgsblandingerne i isbad i 15 minutter, hvorefter det centrifugeres ved 4 0C, 3000 x g i 10 minutter. Pelleten vaskes med 1 ml 6% TCA og centrifugeres som beskrevet ovenfor. Herefter måles pelleten for 14C radioaktivitet i en væskescintillationstæller om 20 måles for ADP-ribosyleringsaktiviteten.
Cellecytotoxicitetsundersøgelse
Undersøgelse af cytotoxicitetsaktiviteten af det modifi-25 cerede PE udførtes i NIH 3T3 cellekulturer og humane KB celler. NIH 3T3 celler eller KB celler såes 24 timer inden cytotoxicitetsforsøget i en 24-brønds vævskulturplade i en tæthed på 2 x 104 pr. brønd. Efter inkubation i 48 timer med forskellige koncentrationer PE eller protein-30 ekstrakter isoleret fra BL21(DEj) med plasmid, der udtrykker forskellige størrelse PE, farves monolaget med methylenblåt for at afsløre overlevende celler. Resultaterne er angivet i tabel 1.
DK 173560 B1 9 Hæmning af proteinsyntese
Undersøgelse over hæmningen af proteinsyntese af PE eller PE med ekstrakter fra B121 (DE3) /pJH8 udføres i schwei-5 siske 3T3 cellekulturer. Schweisiske 3T3 celler udsåes 1 dag inden forsøget i 24 brønd vævskulturplader i en tæthed på 105 celler pr. brønd. Cellerne vaskes en gang med erstatningssubstrat med DMEM og 0,2% BSA inden tilsætning af PE (100 ng/ml) eller PE (100 ng/ml) med 10 ekstrakter, der indeholder en overskydende mængde af forskellige størrelser af PE (tabel 2) , Efter 15 minutter ved 37 0C fjernes substratet og erstattes med frisk DMEM og 0,2% BSA. 4 timer senere undersøges proteinsynte-segraden ved tilsætning af [3H] leucin til substratet 15 (til en slutkoncentration på 2-4 pCi/ml) i 1 time.
I en foretrukken udførelsesform for opfindelsen indføres de strukturelle område af pseudomonas exotoxingenet i en T7 ekspressionsvektor nedenfor ribosombindingspladsen og 20 dens medfølgende ATG initiationscodon (som vist i fig. 1) som beskrevet ovenfor. For at frembringe rekombinante proteiner dyrkes celler ved 37 0C til en Aeso = 0,3. IPTG sættes herefter til 1 mM for at inducere T7 RNA polymerase, og der inkuberes i 2 timer. Der frembringes en 25 række plasmider som angivet i eksempel 1.
Herefter konstrueres en klon, der koder et PE molekyle uden en ledersekvens (pJH4), og hvori en methionin er anbragt nabostillet til alaninen ved aminoenden af den 30 bearbejdede form af nativt PE (tabel 1) . Proteinet frembragt af pJH4 betegnes Met-PE. Store mængder Met-PE frem-. bringes ved indførsel af IPTG, der repræsenterer 20% af det totale celleprotein. ADP ribosyleringsaktivitet svarende til 0,1 mg nativt PE ses i den supernatante del, DK 173560 B1 10 og 0,2 mg i pelleten pr. mg af totalt celleprotein. PE molekylet frembragt af pJH4 er forskellig fra native PE molekyler ved tilstedeværelsen af en ekstra methioninrest ved aminoendestillingen.
5 På grund af den ADP ribosylerende aktivitet af PE rester i carboxylenden af molekylet produceredes plasmid pJH17 opbygget ud fra pJH4 (som angivet ovenfor). Dette plas mid indeholder område III og 20 aminosyrer fra område Ib.
10 Ekstrakter fra dette plasmid indeholder høje niveauer af ADP ribosylerende aktivitet, svarende til 0,06 mg PE (tabel 1) . Ved immunoblotting afsløres et 31 kb protein, der forefindes i en koncentration på 0,3 mg/mg celleprotein.
15
Ingen af plasmiderne frembragt ved ovenfor beskrevne metode (og beskrevet i eksemplerne) bortset fra pJHl, pJH2 og pJH4 udviser signifikant celledræbende evne, skønt mange af disse udviser høj enzymatisk aktivitet (tabel 20 1) . Disse plasmider viser sig at forhindre hæmning af proteinsyntese eller celledrab af nativt PE ved at udsætte celler for 15 minutter nativt PE i en koncentration på 0,1 yg/ml i nærværelse af 3-5 ug/ml forskellige modificerede toxiner. Resultaterne i tabel III viser, at 25 plasmider der udtrykker enten område la alene, eller område I, eller halvdelen af område II og område III forhindrer PE i at hæmme proteinsyntese.
Toxicitet over for dyr 30
Mus, der blev behandlet med nativt PE, døde på grund af levernedbrydning. Den lethale dosis for en mus på 20 g er 0,1-0,2 ug. Resultaterne i tabel IV viser, at PE med en deletion i område la udviser betydelig mindre toxicitet DK 173560 B1 11 over mus. Mus injiceredes intraperitonealt med enten nativt PE eller PE, der manglede området la. Alle mus fik 1,0 pg af det native PE, og halvdelen, der fik 0,2 pg PE, var døde i løbet af 40 timer. To af tre mus, der fik 50 5 pg PE la døde; alle der fik 20 pg PE la levede; og alle mus der fik 5 pg PE la levede. Således er PE la mere end 100 gange mindre toxisk ud fra vægtbasis end det native PE.
10 Genfusioner under anvendelse af rekombinant modificeret Pseudomonas Exotoxin
Genet for det omhandlede modificerede PE specifikt indeholdt i pJH8 kobledes med DNA sekvenser, der kodede for 15 den humane _ transformerende vækstfaktor (a-TGF) eller humant interleukin 2 (IL-2). Se eksempel 6 for nærmere beskrivelse af disse genfusioner. Modificeret PE er velegnet til anvendelse i fusioner med et hvilket som helst peptidhormon, vækstfaktor fra andet polypeptidcel-20 legenkendelsesprotein, for hvilken der eksisterer en specifik receptor på cellen. Få eksempler omfatter: insulin, glucagon, endorphiner, væksthormoner, melanocyt-stimulerende hormon, transferrin, bombesin, lipoprotein med lav massefylde, luteiniserende hormon og asialogly-25 coproteiner.
EKSEMPEL 1
Som angivet i tabel 1 anvendtes den omhandlede fremgangs-30 måde til at opbygge adskillige plasmider indeholder fusioner af forskellig størrelse af det PE strukturelle gen og den T7 sene promotor. pJH7 indeholder genet, der koder for det strukturelle område III af PE (aminosyre 405-613). pJH13 koder PE med en deletion af den første DK 173560 B1 12 halvdel af det strukturelle område II, der omfatter aminosyrerne 253-307. pJH14 koder det strukturelle område la af PE (aminosyrer 1-252). pJH17 koder det strukturelle område III med en yderligere nabostillet sekvens på 20 5 aminosyrer for område Ib {aminosyrer 385-613).
pJH7 blev opbygget ved delvis at afskære pJH4 med Aatll.
Det lineariserede - DNA fragment (5,9 kb) blev herefter fuldstændigt afskåret med Hindlll. 4,7 kb DNA fragmen 10 tet, der har Aatll og Hindlll pladser ved enderne efter adskillelse inkuberedes med SI nuclease for at fjerne de cohæsive ender, hvorefter der ligeredes med T4 ligase.
pJH13 blev opbygget ved delvis at afskære pJH4 med Aval.
15 Det lineariserede DNA fragment blev herefter fuldstændigt afskåret med EcoRI. 4,7 kb DNA’en, der havde Aval og EcoRI afskærings ved begge ender inkuberedes med SI for at fjerne de cohæsive ender (DNA fragment 1). pJH4 blev delvis afskåret med Sall. Det lineariserede DNA fragment 20 blev herefter fuldstændigt afskåret med EcoRI. 1,0 kb DNA fragmentet, der havde Sall og EcoRI pladser ved enderne inkuberedes med klenow DNA polymerase I og dNTP for at udfylde de cohæsive ender (DNA fragment 2). DNA fragment 1 (4,7 kb) og DNA fragment 2 (1,0 kb) ligeredes natten 25 over ved 4 OC.
pJH14 blev opbygget ved delvis at afskære pJH4 med Aval.
Det lineariserede DNA fragment blev herefter fuldstændigt afskåret med EcoRI. 4,7 kb DNA'en, der har Aval og EcoRI 30 pladser ved enderne, inkuberedes med SI for at fjerne den cohæsive ende, hvorefter der ligeredes med T4 ligase.
pJH17 opbyggedes som beskrevet tidligere.
DK 173560 B1 13 EKSEMPEL 2 Mængden og aktiviteten af de rekombinante toxiner (frembragt af plasmiderne beskrevet i eksempel 1) blev målt 5 ved SDS-PAGE, ADP-ribosylering og celledræbende evne. Resultaterne er angivet i tabel 1.
EKSEMPEL 3 10 Forsøgene udførtes for at undersøge egenskaberne af det omhandlede rekombinante materiale. Resultaterne er angivet i tabel 2.
EKSEMPEL 4 15
Virkningen af forskellige deletioner på celleproteinsyn-tesen bestemtes med og uden nativt PE. Resultaterne er angivet i tabel 3. Det strukturelle område la (pJH14) og det strukturelle område I, halvdelen af II og II (pJH13) 20 ekstraheredes fra pellen af lydbehandlede celler med 8 M urinstof. 10 μΐ af hver ekstrakt svarende til 3-5 pg re-kombinant protein anvendtes i hvert forsøg. Strukturelt II, Ib og III (pJH8) forefandtes i den supernatante del af lydbehandlede BL21 (DEj)/pJH8 celler. 10 yl ekstrakt 25 svarende til 2 pg rekombinant toxin anvendtes. Cellerne behandledes som angivet i tabel 3 i 15 minutter med og uden nativt PE i en koncentration på 0,1 pg/ml efterfulgt af 1 ml DMEM vask; inkubering i 4 timer i DMEM og 0,2% BSA, herefter inkubering med 3H-leucin i 1 time.
30 EKSEMPEL 5
Som angivet i tabel 4 bestemtes den dosis der bevirkede drab på mus ved at injicere Balb/c mus intraperitonealt 14 DK 173560 B1 med forskellige mængder PE eller PE la indeholdt i 1,0 ml sterilt saltvand og 10 mg/ml sterilt humant albumin.
Dyrene kontrolleredes dagligt i 2 uger. Alle dødsfald forekom indenfor 48 timer.
5 EKSEMPEL 6
Opbygning af IL-2-PE fusionsgen 10 pVC8 blev afskåret med Avail ved stilling 1190, 3,6 fragmentet isoleredes, dets enkeltstrengede ender udfyldtes med klenowenzym og dephosphoryleredes til frembringelse af fragment I. Klon PST-5 [Gallo et al., PNAS, 81:2543— 2547 (1984)] blev afskåret med PstI til frembringelse af 15 et 1 kD fragment af IL-2, der herefter blev afskåret med Bsp 128 6 ved stilling 105 og 669 og behandlet med T4 polymerase for at udfylde enderne. 564 bp fragmentet ligeredes til fragment I til frembringelse af pHL-1 og transformeredes ind i BL21 ekspressionsceller. Ved 20 indførsel frembragtes et 60 kD protein, der reagerer med antistoffer over for IL-2 og over for PE, og som indeholder ADP-ribosylerende aktivitet.
25 30 DK 173560 B1 15 TABEL 1 9
Oversigt over mængde og aktivitet af rekombinante toxiner 5 målt ved SDS-PAGE, ADP-ribosylering og celledrabseksperimenter .
Mængde af PE pr. mg cellulært protein 10 Målt ved Målt ved ADP-ribo- Målt ved SDS-PAGE sylering celledrab (mg) (enheder) (enheder) 15 Total Sup. Pellet Sup. Pellet pJH3 nedbrudt <0,001 <0,001 N.D. N.D.
pJH4 0,203 0,10 0,20 <0,001 0,2 pJH7 0,25·'3 <0,001 <0,001 <0,001 <0,001 20 pJH9 0, 153 0, 40 0,20 <0,001 <0,001 pJHlO 0, 15a 0, 40 0, 15 <0,001 <0,001 pJH13 0, 01 0,25 0,20 <0,001 <0,001 pJH14 0, 30a <0,001 <0,001 <0,001 <0,001 pJH17 0, 03°'" 0,06 <0,001 <0,001 <0,001 25 pJHl 8 <0,01n 0,02 N.D. N.D. N.D.
* 1 enheder ADP-ribosylering eller celledrabsaktivitet er ækvivalent med aktiviteten 1 mg nativt PE.
30 N.D. = ikke bestemt a = aggregeret o = positive ved Western
n = ikke synlig på SDS PAGE
16 DK 173560 B1 TABEL 2 5 Tilstedeværende Protein
Opbygning område_ størrelse pJH7 III 28 kd pJH13 I, halvdelen 10 af II, III 63 kd pJH14 la 32 kd pJH17 20 a.a. af Ib, III 31 kd 15 TABEL 3 20 3H-leucin stammende fra (cpm x 103)
Med PE
Område undersøgt Uden PE (I, II, III) 25 Ingen 11,2 ± 0,1 2,3 ± 0,2 la 11,5 ± 0,15 9,4 ± 0,3 II, Ib & III 11,7 ± 0,15 2,4 ± 0,2 I, 1/2 II, III 10,7 ± 0,15 9,2 ± 0,2 8 M urinstof (10 μΐ) 11,1 ± 0,1 2,9 ± 0,2 30 DK 173560 B1 17 TABEL 4
Toxin Dosis Døde 5 PE 50 2/3 PE45 20 0/3 PE45 5 0/3 PE45 10 3/3 10 PE 1/0 3/3 PE 0,3 3/3 PE 0,2 1/3 PE 0,1 0/3 15 Følgende plasmider er deponeret i American Type Culture Collection i Rockville, Maryland under de respektive angivne ATCC numre inden indlevering af denne ansøgning, og ved udstedelse af denne ansøgning til et patent vil de være opretholdt i et tidsrum på 30 år fra deponerings-20 datoen eller 5 år efter sidste anmodning om en sådan deponering eller i hele patentets levetid, uafhængig af hvilken der er længst. Deponeringerne vil blive erstattet dersom kulturerne muterer eller ikke er levedygtige under deponeringstiden: 25 pJH12 ATCC 67205 pHL-1 ATCC 67206 pVC33 ATCC 67207 pJH81 ATCC 67208 30 pJH14 . ATCC 67209
Claims (22)
1. Modificeret pseudomonas exotoxin omfattende ADP 5 ribosylerende aktivitet og som mangler hele eller en del af domæne II fra det native toxin.
2. Modificeret pseudomonas exotoxin ifølge krav 1, kendetegnet ved, at exotoxinet omfatter en 10 modifikation i receptor bindingsdomænet la af det native toxin, som er tilstrækkelig til at gøre det modificerede toxin mindre toxisk overfor humane eller dyreceller in vitro og mindre toxisk overfor leveren, når det administreres in vivo, i forhold til et ikke-modificeret 15 pseudomonas exotoxin.
3. Target bærer-toxin konjugat egnet til anvendelse til mennesker eller pattedyr omfattende et toxin koblet til en target bærer, kendetegnet ved, at nævnte 20 toxin er et modificeret Pseudomonas exotoxin ifølge krav 1 eller 2.
4. Konjugat ifølge krav 2, kendetegnet ved, at nævnte target bærer er valgt blandt gruppen, der består 25 af et antigen, et antistof, en vækstfaktor, et hormon, en lymphokin, et polypeptid celle-genkendelsesprotein, et serum protein, et modificeret serum protein, et endorphin, et asiaglycoprotein, insulin, glucagon, luteiniserende hormon, fibroplast vækstfaktor, nerve 30 vækstfaktor, melanocyt-stimulerende hormon, bombesin og et lectin.
5. Konjugat ifølge krav 2, kendetegnet ved, at nævnte target bærer er valgt blandt gruppen, der består DK 173560 B1 19 af interleukin 2 og alpha transformerende vækstfaktor og et peptid hormon.
6. Immunotoxin egnet til anvendelse til mennesker eller 5 dyr omfattende et toxin koblet til et antistof/ som kan genkende syge eller sygdomsvækkende celler/ kendetegnet ved, at nævnte toxin er et modificeret pseudomonas exotoxin ifølge krav 1 eller 2.
7. Immunotoxin ifølge krav 6, kendetegnet ved, at nævnte exotoxin indeholder domæne III og naboliggende 20 aminosyrer fra pseudomonas exotoxin.
8. Immunotoxin ifølge krav 6, kendetegnet ved, 15 at nævnte exotoxin er det rekorobinante pseudomonas exotoxin kodet af plasmid pJH17, indholdende 4,8 kb Hindlll/Apal fragmentet af pJH4, der koder for domæne III med de naboliggende 20 aminosyrer fra domæne Ib, kendetegnet ved, at 4,8 kb fragmentet kan opnås fra 20 pJH4 i figur 1.
9. Immunotoxin ifølge krav 6, kendetegnet ved, at nævnte exotoxin er rekombinant pseudomonas exotoxin kodet af plasmid pJH7. 25
10. Immunotoxin ifølge krav 6, kendetegnet ved, at nævnte exotoxin er rekombinant pseudomonas exotoxin kodet af plasmid pJH9.
11. Immunotoxin ifølge krav 6, kendetegnet ved, at nævnte exotoxin er rekombinant pseudomonas exotoxin kodet af plasmid pJHIO. DK 173560 B1 20
12. Immunotoxin ifølge krav 6, kendetegnet ved, at nævnte exotoxin er rekombinant pseudomonas exotoxin kodet af plasmid pJH13.
13. Ekspressionsplasmid omfattende DNA, som koder for et hvilket som helst af proteinerne ifølge krav 1 til 8.
14. Fremgangsmåde til fremstilling af et modificeret pseudomonas exotoxin ifølge krav 1 eller 2 omfattende at 10 transfektere en egnet værtscelle med et plasmid omfattende DNA, som koder for nævnte modificerede exotoxin, og at dyrke nævnte værtscelle under betingelser, hvorved nævnte modificerede pseudomonas exotoxin frembringes. 15
15. Fremgangsmåde til fremstilling af et immunotoxin ifølge krav 5 omfattende a) at transfektere en egnet værtscelle med et plasmid, 20 der koder for det modificerede pseudomonas exotoxin ifølge krav 1 eller 2, b) at dyrke nævnte værtscelle under betingelser, hvorved nævnte modificerede pseudomonas exotoxin frembringes, og 25 c) at konjugere nævnte modificerede exotoxin med et antistof til dannelse af et immunotoxin.
16. Fremgangsmåde ifølge krav 15, kendetegnet 30 ved, at nævnte pseudomonas exotoxin gen indeholder domæne III og de naboliggende 20 aminosyrer fra pseudomonas exotoxin. DK 173560 B1 21
17. Fremgangsmåde til fremstilling af en target bærer pseudomonas konjugat ifølge krav 2, omfattende at transfektere en egnet værtscelle med et plasmid omfattende en DNA sekvens, der koder for nævnte target 5 bærerkonjugat, og at dyrke nævnte værtscelle under betingelser, hvorved et target bærer pseudomonas exotoxin konjugat frembringes.
18. Sammensætning egnet til administrering til et 10 pattedyr til opnåelse af target cytotoxisk aktivitet i nævnte pattedyr, kendetegnet ved, at sammensætningen omfatter et konjugat ifølge et hvilket som helst af kravene 2 til 12 i en farmaceutisk acceptabel bærer. 15
19. Modificeret pseudomonas exotoxin ifølge krav 1 eller 2, kendetegnet ved, at nævnte exotoxin er blevet genetisk modificeret.
20. Et antigen-toxin konjugat ifølge krav 3, kendetegnet ved, at nævnte exotoxin er blevet modificeret ved rekombinant teknikker.
21. Anvendelse af et exotoxin ifølge krav 1 eller 2 af et 25 exotoxin kodet af et plasmid ifølge krav 13 til fremstilling af en vaccine til aktiv immunisering.
22. Anvendelse af et konjugat ifølge et hvilket som helst af kravene 2 til 12 ti fremstilling af et medikament til 30 behandling af cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/911,227 US4892827A (en) | 1986-09-24 | 1986-09-24 | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
US91122786 | 1986-09-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
DK199901377A DK199901377A (da) | 1999-09-28 |
DK173560B1 true DK173560B1 (da) | 2001-03-12 |
Family
ID=25429936
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK198802764A DK173301B1 (da) | 1986-09-24 | 1988-05-20 | Rekombinant pseudomonas exotoxin med modifikation i receptor bindingsdomænet Ia, target bærer-toxin konjugat, immunotoxiner |
DK199901377A DK173560B1 (da) | 1986-09-24 | 1999-09-28 | Rekombinant pseudomonas exotoxin omfattende ADP ribosylerende aktivitet og som mangler hele eller en del af domæne II fra d |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK198802764A DK173301B1 (da) | 1986-09-24 | 1988-05-20 | Rekombinant pseudomonas exotoxin med modifikation i receptor bindingsdomænet Ia, target bærer-toxin konjugat, immunotoxiner |
Country Status (19)
Country | Link |
---|---|
US (2) | US4892827A (da) |
EP (2) | EP0261671B1 (da) |
JP (3) | JP2848489B2 (da) |
KR (1) | KR970001563B1 (da) |
AT (2) | ATE311442T1 (da) |
AU (1) | AU618722B2 (da) |
CA (1) | CA1336691C (da) |
DE (2) | DE3789587T2 (da) |
DK (2) | DK173301B1 (da) |
ES (2) | ES2074042T3 (da) |
FI (1) | FI105271B (da) |
IE (1) | IE66223B1 (da) |
IL (2) | IL105160A (da) |
NO (1) | NO180270C (da) |
NZ (1) | NZ221923A (da) |
PT (1) | PT85777B (da) |
SG (1) | SG96159A1 (da) |
WO (1) | WO1988002401A1 (da) |
ZA (1) | ZA877153B (da) |
Families Citing this family (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5668255A (en) * | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
US6022950A (en) * | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
US5169939A (en) * | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
US6051405A (en) * | 1986-09-24 | 2000-04-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Constructs encoding recombinant antibody-toxin fusion proteins |
US4892827A (en) * | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
AU3751689A (en) * | 1988-05-09 | 1989-11-29 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Vector for secretion of proteins directly into periplasm or culture medium |
US5206353A (en) * | 1988-07-23 | 1993-04-27 | The United States Of America As Represented By The Department Of Health And Human Services | CD-4/cytotoxic gene fusions |
US5169933A (en) * | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
US5135736A (en) * | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
US5149782A (en) * | 1988-08-19 | 1992-09-22 | Tanox Biosystems, Inc. | Molecular conjugates containing cell membrane-blending agents |
ZA898139B (en) * | 1988-11-17 | 1990-08-29 | Hoffmann La Roche | Recombinant interleukin-2 hybrid proteins |
DK0383599T3 (da) * | 1989-02-17 | 1996-08-05 | Merck & Co Inc | Protein-anticancermiddel |
US6406697B1 (en) * | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
US5621078A (en) * | 1989-03-22 | 1997-04-15 | Merck & Co., Inc. | Modified pseudomonas exotoxin PE40 |
IL93723A (en) * | 1989-03-22 | 1997-02-18 | Merck & Co Inc | Cystein modified truncated pseudomonas exotoxin A |
AU641392B2 (en) * | 1989-04-21 | 1993-09-23 | Protein Design Laboratories, Inc. | Recombinant antibody-toxin fusion protein |
US6207798B1 (en) | 1989-08-03 | 2001-03-27 | Merck & Co., Inc. | Modified PE40 toxin fusion proteins |
US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
US6329508B1 (en) | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
US5527527A (en) * | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
CA2071946A1 (en) * | 1989-12-21 | 1991-06-22 | Ira H. Pastan | Toxin for construction of immunotoxins |
CA2072891C (en) * | 1990-01-02 | 1999-12-21 | Ira Pastan | Pseudomonas exotoxin fusion proteins having carboxyl alterations with increased cytotoxicity |
US5458878A (en) * | 1990-01-02 | 1995-10-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity |
US5110912A (en) * | 1990-03-02 | 1992-05-05 | Seragen, Inc. | Purification of il-2-containing hybrid compounds |
DK0531434T3 (da) * | 1990-05-11 | 2000-01-31 | Us Health | Forbedrede Pseudomonas-exotoksiner med lav dyretoksicitet og høj cytocidal aktivitet |
IL98528A0 (en) * | 1990-06-21 | 1992-07-15 | Merck & Co Inc | Pharmaceutical compositions containing hybrid for killing bladder cancer cells |
US5241053A (en) * | 1990-09-05 | 1993-08-31 | Takeda Chemical Industries, Ltd. | Fused proteins comprising glycoprotein gD of HSV-1 and LTB |
US6099842A (en) * | 1990-12-03 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin |
US5571894A (en) * | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
CA2079879C (fr) * | 1991-02-08 | 2007-11-06 | Thierry Hercend | Sequences nucleotidiques codant pour des regions variables de chaines alpha des recepteurs des lymphocytes humains ainsi que leurs applications |
FR2672616B1 (fr) * | 1991-02-08 | 1994-09-23 | Roussel Uclaf | Sequences nucleotidiques codant pour des regions variables de chaines alpha des recepteurs de lymphocytes t humains, segments peptidiques correspondants et les applications diagnostiques et therapeutiques. |
CA2079881C (fr) * | 1991-02-12 | 2007-11-06 | Thierry Hercend | Sequences nucleotidiques codant pour des regions variables de chaines .beta. des recepteurs des lymphocytes t humains, segments peptidiques correspondants et les applications diagnostiques et therapeutiques |
US5328984A (en) * | 1991-03-04 | 1994-07-12 | The United States As Represented By The Department Of Health & Human Services | Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells |
US5223604A (en) * | 1991-06-25 | 1993-06-29 | S.P.I. Synthetic Peptides Incorporated | Pseudomonas exoenzyme s peptide composition and method |
US5939531A (en) * | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
CA2081952A1 (en) * | 1991-11-08 | 1993-05-09 | John J. Donnelly | Recombinant dna sequences and plasmids for cellular immunity vaccines from bacterial toxin-antigen conjugates, and methods of their use |
ATE314475T1 (de) * | 1992-06-18 | 2006-01-15 | Us Gov Health & Human Serv | Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität |
GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
US6015555A (en) * | 1995-05-19 | 2000-01-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
AU706056B2 (en) * | 1995-10-13 | 1999-06-10 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Immunotoxin containing a disulfide-stabilized antibody fragment |
HUP9901109A3 (en) | 1996-03-01 | 1999-11-29 | Novartis Ag | Peptide immunogens for vaccination against and treatment of allergy |
EP0941334B1 (en) | 1996-11-06 | 2004-06-02 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Protease-activatable pseudomonas exotoxin a-like proproteins |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US20020004113A1 (en) * | 1997-06-26 | 2002-01-10 | Weder Donald E. | Decorative cover for flower pot or floral grouping formed of polymeric materials having a texture or appearance simulating the texture or appearance of paper |
US20030198772A1 (en) * | 1997-06-26 | 2003-10-23 | Weder Donald E. | Polymeric materials having a texture or appearance simulating the texture or appearance of paper |
US7314632B1 (en) * | 1997-07-11 | 2008-01-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pseudomonas exotoxin A-like chimeric immunogens |
AU731703B2 (en) * | 1997-07-11 | 2001-04-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Pseudomonas exotoxin A-like chimeric immunogens |
US20030054012A1 (en) * | 2000-05-12 | 2003-03-20 | Fitzgerald David J. | Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response |
US6077676A (en) * | 1997-12-18 | 2000-06-20 | Spectral Diagnostics, Inc. | Single-chain polypeptides comprising troponin I and troponin C |
US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
AU2004201055B2 (en) * | 1998-04-24 | 2007-08-23 | The Regents Of The University Of California | Internalizing ErbB2 antibodies |
US6794128B2 (en) * | 1998-04-24 | 2004-09-21 | The Regents Of The University Of California | Methods of selecting internalizing antibodies |
US20020142000A1 (en) * | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
US20030143233A1 (en) * | 1999-06-07 | 2003-07-31 | Neorx Corporation | Streptavidin expressed gene fusions and methods of use thereof |
US20030103948A1 (en) * | 1999-06-07 | 2003-06-05 | Neorx Corporation | Streptavidin expressed gene fusions and methods of use thereof |
US7144991B2 (en) | 1999-06-07 | 2006-12-05 | Aletheon Pharmaceuticals, Inc. | Streptavidin expressed gene fusions and methods of use thereof |
US6838553B1 (en) * | 1999-10-05 | 2005-01-04 | Academia Sinica | Peptide repeat immunogens |
US7078486B2 (en) * | 1999-12-10 | 2006-07-18 | Spectral Diagnostics, Inc. | Single-chain polypeptides comprising troponin I and troponin C |
US20030104987A1 (en) * | 2001-04-25 | 2003-06-05 | Weigel Paul H. | Methods of using the hyaluronan receptor for endocytosis |
CA2410024A1 (en) * | 2000-04-25 | 2001-11-01 | The Board Of Regents Of The University Oklahoma | Identification and uses of a hyaluronan receptor |
US20050287638A1 (en) * | 2000-04-25 | 2005-12-29 | Weigel Paul H | Hyaluronan receptor for endocytosis, variants thereof, and methods of making and using same |
EP1379550B1 (en) * | 2000-12-21 | 2009-03-11 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences |
ES2342929T3 (es) | 2001-09-26 | 2010-07-19 | The Government of the United States of America as represented by the Secretary of Health and Human | Anticuerpos anti-cd22 con afinidad aumentada por las celulas leucemicas que expresan cd22. |
CA2466443A1 (en) * | 2001-11-09 | 2003-05-15 | Neopharm, Inc. | Selective treatment of il-13 expressing tumors |
WO2004087758A2 (en) * | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
CN100417414C (zh) | 2003-04-30 | 2008-09-10 | 苏黎世大学 | 免疫毒素在制备治疗头颈鳞状上皮细胞癌或膀胱癌药物中的应用 |
EP1689783B1 (en) * | 2003-11-25 | 2010-05-19 | The Government Of The United States, As Represented by The Secretary Of Health And Human Services | Mutated anti-cd22 antibodies and immunoconjugates |
WO2006039238A2 (en) * | 2004-09-30 | 2006-04-13 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Irta2 antibodies and methods of use |
CA2583226A1 (en) | 2004-10-04 | 2006-04-20 | Trinity Biosystems, Inc. | Methods and compositions for immunizing against pseudomonas infection |
CA2583202A1 (en) * | 2004-10-04 | 2006-04-27 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of macromolecules |
CA2591992A1 (en) | 2004-12-22 | 2006-06-29 | The Salk Institute For Biological Studies | Compositions and methods for producing recombinant proteins |
AU2006247188A1 (en) | 2005-05-18 | 2006-11-23 | Children's Hospital & Research Center At Oakland | Methods and compositions for immunizing against chlamydia infection |
WO2007016150A2 (en) | 2005-07-29 | 2007-02-08 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH | Mutated pseudomonas exotoxins with reduced antigenicity |
US20070148131A1 (en) * | 2005-12-05 | 2007-06-28 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of binding partners |
CA2631952A1 (en) * | 2005-12-05 | 2007-06-14 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of antibodies |
EP2010205A2 (en) | 2006-03-16 | 2009-01-07 | Trinity Biosystems, Inc. | Methods for increasing the size of animals using needleless delivery constructs |
EP1878744A1 (en) * | 2006-07-13 | 2008-01-16 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them |
US20090092660A1 (en) * | 2006-08-09 | 2009-04-09 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of particles |
WO2009014650A2 (en) | 2007-07-20 | 2009-01-29 | The General Hospital Corporation | Recombinant vibrio cholerae exotoxins |
EP2197903B9 (en) | 2007-09-04 | 2015-04-22 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity |
CN108129573B (zh) * | 2007-09-21 | 2021-10-08 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
JP5836125B2 (ja) | 2008-10-16 | 2015-12-24 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用 |
WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
CN102655882B (zh) | 2009-09-11 | 2014-11-19 | 美国政府健康及人类服务部 | 具有降低的免疫原性的改进的假单胞菌外毒素a |
WO2011100455A1 (en) | 2010-02-12 | 2011-08-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inhibition of antibody responses to foreign proteins |
NZ602958A (en) | 2010-03-30 | 2014-07-25 | Pfenex Inc | High level expression of recombinant toxin proteins |
WO2011159835A1 (en) | 2010-06-16 | 2011-12-22 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Antibodies to endoplasmin and their use |
CA2806314C (en) | 2010-07-30 | 2019-09-24 | Medimmune, Llc | Method for purifying active polypeptides or immunoconjugates |
US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
TWI689314B (zh) * | 2010-11-30 | 2020-04-01 | 建南德克公司 | 低親和力血腦障壁受體抗體及其用途 |
US9206257B2 (en) | 2011-04-19 | 2015-12-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
AU2012268013B2 (en) | 2011-06-09 | 2016-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes |
US8932586B2 (en) | 2011-09-06 | 2015-01-13 | Intrexon Corporation | Modified forms of Pseudomonas exotoxin A |
WO2013039916A1 (en) | 2011-09-12 | 2013-03-21 | The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Compositions for and methods of treatment and enhanced detection of non-pituitary tumors |
US9206240B2 (en) | 2011-09-16 | 2015-12-08 | The United States of America, as represented by the Secretary, Department of Helath and Human Services | Pseudomonas exotoxin A with less immunogenic B cell epitopes |
EP2764025B1 (en) | 2011-10-04 | 2017-11-29 | IGEM Therapeutics Limited | Ige-antibodies against hmw-maa |
US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
CN104520331B (zh) | 2012-06-01 | 2018-09-07 | 美国政府(由卫生和人类服务部的部长所代表) | 磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途 |
AU2013306076B2 (en) | 2012-08-21 | 2018-01-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin domain-specific monoclonal antibodies and use thereof |
US9416190B2 (en) | 2012-09-27 | 2016-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
WO2014089354A1 (en) | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
WO2014093240A1 (en) | 2012-12-10 | 2014-06-19 | The General Hospital Corporation | Bivalent il-2 fusion toxins |
CN105007937B (zh) | 2012-12-20 | 2019-11-19 | 米迪缪尼有限公司 | 生产免疫偶联物的方法 |
US9790282B2 (en) | 2013-03-25 | 2017-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 polypeptides, proteins, and chimeric antigen receptors |
US10093745B2 (en) | 2013-05-29 | 2018-10-09 | The Regents Of The University Of California | Anti-CSPG4 fusions with interferon for the treatment of malignancy |
US9388222B2 (en) | 2013-10-06 | 2016-07-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified Pseudomonas exotoxin A |
ES2764833T3 (es) | 2013-10-11 | 2020-06-04 | The United States Of America Represented By The Sec Dep Of Health And Human Services | Anticuerpos contra TEM8 y su uso |
EP3066118B1 (en) | 2013-11-06 | 2020-01-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
AU2014352638B2 (en) | 2013-11-25 | 2018-08-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control HIV infection |
US10421958B2 (en) | 2014-02-05 | 2019-09-24 | Molecular Templates, Inc. | Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity |
BR112016025866A2 (pt) | 2014-05-07 | 2017-12-12 | Applied Molecular Transp Llc | composição farmacêutica, método para tratar uma doença anti-inflamatória em um indivíduo, método para tratar uma doença autoimune em um indivíduo, método para tratar um câncer em um indivíduo, uso de uma molécula de fusão que não ocorre naturalmente, método para tratar um distúrbio metabólico em um indivíduo, método para tratar uma doença hepática gordurosa em um indivíduo, método para tratar um distúrbio de deficiência de hormônio de crescimentoem um indivíduo, e, polinucleotídeo que codifica uma molécula de fusão |
ES2848857T3 (es) | 2014-07-31 | 2021-08-12 | Us Gov Health & Human Services | Anticuerpos monoclonales humanos contra EphA4 y su uso |
CA2961609C (en) | 2014-09-17 | 2023-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 antibodies (b7h3) |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
CA2981509A1 (en) | 2015-03-30 | 2016-10-06 | The Board Of Regents Of The Nevada System Of Higher Educ. On Behalf Of The University Of Nevada, La | Compositions comprising talens and methods of treating hiv |
US20180161429A1 (en) | 2015-06-26 | 2018-06-14 | Beth Israel Deaconess Medical Center Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
WO2017064190A1 (en) | 2015-10-13 | 2017-04-20 | Sanofi Pasteur | Immunogenic compositions against s. aureus |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
CN108473575B (zh) | 2015-11-13 | 2022-04-19 | 美国卫生和人力服务部 | 抗-bcma多肽和蛋白质 |
WO2017196847A1 (en) | 2016-05-10 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens |
WO2017214182A1 (en) | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Fully human antibody targeting pdi for cancer immunotherapy |
US11066479B2 (en) | 2016-08-02 | 2021-07-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof |
CA3045902A1 (en) | 2016-12-21 | 2018-06-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for flt3 and uses thereof |
US11390683B2 (en) | 2017-05-18 | 2022-07-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin polypeptides and proteins |
US11389480B2 (en) | 2017-05-19 | 2022-07-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibody targeting TNFR2 for cancer immunotherapy |
WO2019005208A1 (en) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY |
WO2019006280A1 (en) | 2017-06-30 | 2019-01-03 | Lentigen Technology, Inc. | HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE |
US10849960B2 (en) | 2017-09-08 | 2020-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer |
US11795235B2 (en) | 2017-09-18 | 2023-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotoxins with albumin binding domain |
EP3691693A4 (en) | 2017-10-06 | 2021-08-25 | University Of Utah Research Foundation | FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE |
ES2920428T3 (es) | 2018-03-08 | 2022-08-03 | Applied Molecular Transport Inc | Constructos de administración derivados de toxinas para la administración oral |
JP7459043B2 (ja) | 2018-07-12 | 2024-04-01 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 親和性成熟cd22特異的モノクローナル抗体およびその使用 |
US12012463B2 (en) | 2018-08-08 | 2024-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-2 and uses thereof |
KR102353086B1 (ko) * | 2018-09-07 | 2022-01-20 | 아주대학교산학협력단 | 신규 면역독소 제조방법 |
IL282986B2 (en) | 2018-11-07 | 2024-01-01 | Applied Molecular Transport Inc | Colics-derivative carriers for oral administration of heterologous cargo |
SG11202104721RA (en) | 2018-11-07 | 2021-06-29 | Applied Molecular Transport Inc | Delivery constructs for transcytosis and related methods |
US20220064324A1 (en) | 2019-01-08 | 2022-03-03 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Cross species single domain antibodies targeting mesothelin for treating solid tumors |
CN113784987A (zh) | 2019-01-22 | 2021-12-10 | 美国政府(由卫生和人类服务部的部长所代表) | 靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法 |
US20220127368A1 (en) | 2019-02-19 | 2022-04-28 | The Regents Of The University Of Colorado, A Body Corporate | Bispecific immunotoxins targeting human cd25+ccr4+ tumors and regulatory t-cells |
EA202290208A1 (ru) | 2019-07-02 | 2022-03-25 | Дзе Юнайтед Стейтс Оф Эмерика, Эз Репрезентед Бай Дзе Секретэри, Дипартмент Оф Хелт Энд Хьюман Сервисиз | МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ EGFRvIII, И ИХ ПРИМЕНЕНИЕ |
WO2021034727A1 (en) | 2019-08-16 | 2021-02-25 | Applied Molecular Transport Inc. | Compositions, formulations, and interleukin production and purification |
EP4031250A1 (en) | 2019-10-22 | 2022-07-27 | The United States of America, as represented by the Secretary, Department of Health and Human Services | High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors |
WO2021097289A1 (en) | 2019-11-15 | 2021-05-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pegylated recombinant immunotoxins |
WO2021173674A1 (en) | 2020-02-26 | 2021-09-02 | A2 Biotherapeutics, Inc. | Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof |
WO2022093745A1 (en) | 2020-10-26 | 2022-05-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting sars coronavirus spike protein and uses thereof |
MX2023007178A (es) | 2020-12-22 | 2023-06-30 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Complejo de anticuerpo anti-il-4r o fragmento de enlace a antigeno y uso medico del mismo. |
WO2022232612A1 (en) | 2021-04-29 | 2022-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lassa virus-specific nanobodies and methods of their use |
CN117500831A (zh) | 2021-06-09 | 2024-02-02 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体 |
WO2023076881A1 (en) | 2021-10-26 | 2023-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein |
WO2023114980A1 (en) | 2021-12-17 | 2023-06-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors |
WO2024050399A1 (en) | 2022-09-01 | 2024-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes |
WO2024104584A1 (en) | 2022-11-17 | 2024-05-23 | University Of Cape Town | Deimmunized pseudomonas exotoxin a |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4470924A (en) * | 1981-12-30 | 1984-09-11 | Iglewski Barbara M | Nontoxic, immunologically crossreactive toxin A protein from Pseudomonas aeruginosa |
DE3369466D1 (en) * | 1982-05-12 | 1987-03-05 | Harvard College | Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof |
US4545985A (en) * | 1984-01-26 | 1985-10-08 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Pseudomonas exotoxin conjugate immunotoxins |
US4894443A (en) * | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
NZ212312A (en) * | 1984-06-07 | 1988-09-29 | John Richard Murphy | Hybrid protein comprising fragments of diphtheria toxin and part of cell-specific ligand; and fused gene therefor |
US4892827A (en) * | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
US4867962A (en) * | 1988-02-26 | 1989-09-19 | Neorx Corporation | Functionally specific antibodies |
-
1986
- 1986-09-24 US US06/911,227 patent/US4892827A/en not_active Expired - Lifetime
-
1987
- 1987-09-22 AU AU80211/87A patent/AU618722B2/en not_active Expired
- 1987-09-22 IL IL105160A patent/IL105160A/xx not_active IP Right Cessation
- 1987-09-22 KR KR1019880700570A patent/KR970001563B1/ko not_active IP Right Cessation
- 1987-09-22 JP JP62505905A patent/JP2848489B2/ja not_active Expired - Lifetime
- 1987-09-22 IL IL8397187A patent/IL83971A/en not_active IP Right Cessation
- 1987-09-22 WO PCT/US1987/002373 patent/WO1988002401A1/en active IP Right Grant
- 1987-09-22 IE IE255387A patent/IE66223B1/en not_active IP Right Cessation
- 1987-09-23 ZA ZA877153A patent/ZA877153B/xx unknown
- 1987-09-23 EP EP87113929A patent/EP0261671B1/en not_active Expired - Lifetime
- 1987-09-23 PT PT85777A patent/PT85777B/pt unknown
- 1987-09-23 DE DE3789587T patent/DE3789587T2/de not_active Expired - Lifetime
- 1987-09-23 EP EP93113917A patent/EP0583794B1/en not_active Expired - Lifetime
- 1987-09-23 AT AT93113917T patent/ATE311442T1/de not_active IP Right Cessation
- 1987-09-23 NZ NZ221923A patent/NZ221923A/en unknown
- 1987-09-23 ES ES87113929T patent/ES2074042T3/es not_active Expired - Lifetime
- 1987-09-23 CA CA000547614A patent/CA1336691C/en not_active Expired - Fee Related
- 1987-09-23 ES ES93113917T patent/ES2253734T3/es not_active Expired - Lifetime
- 1987-09-23 AT AT87113929T patent/ATE104153T1/de not_active IP Right Cessation
- 1987-09-23 DE DE3752387T patent/DE3752387T2/de not_active Expired - Lifetime
- 1987-09-23 SG SG9607253A patent/SG96159A1/en unknown
-
1988
- 1988-05-20 DK DK198802764A patent/DK173301B1/da not_active IP Right Cessation
- 1988-05-24 NO NO882269A patent/NO180270C/no unknown
-
1989
- 1989-03-21 FI FI891321A patent/FI105271B/fi not_active IP Right Cessation
-
1995
- 1995-06-05 US US08/463,163 patent/US5696237A/en not_active Expired - Lifetime
-
1997
- 1997-05-26 JP JP9135626A patent/JP2960697B2/ja not_active Expired - Fee Related
-
1998
- 1998-11-16 JP JP10324676A patent/JP3053087B2/ja not_active Expired - Lifetime
-
1999
- 1999-09-28 DK DK199901377A patent/DK173560B1/da not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK173560B1 (da) | Rekombinant pseudomonas exotoxin omfattende ADP ribosylerende aktivitet og som mangler hele eller en del af domæne II fra d | |
JP3589459B2 (ja) | 生物応答調節物質の新規な抗体運送システム | |
AU665360B2 (en) | Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis | |
EP0646175B1 (en) | Recombinant pseudomonas exotoxin with increased activity | |
JP4940136B2 (ja) | キメラタンパク質およびその使用 | |
AU665763B2 (en) | Interleukin receptor targeted molecules for treatment of inflammatory arthritis | |
JPH04506976A (ja) | 免疫毒素の構築のための改良された毒素 | |
CN100365022C (zh) | 新的融合毒素蛋白质及其应用 | |
US20120232010A1 (en) | Compositions and Methods for Treating Bladder Cancer | |
CN1293205A (zh) | 与短肽激素嵌合的靶特异性细胞毒性剂 | |
IE84490B1 (en) | Recombinant pseudomonas exotoxin: construction of an active immunotoxin with low side effects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B1 | Patent granted (law 1993) | ||
PUP | Patent expired |